Prolight Diagnostics（PRLD）株式概要Prolight Diagnostics AB (publish)は、スウェーデンでポイントオブケア検査に使用される診断システムを開発している。 詳細PRLD ファンダメンタル分析スノーフレーク・スコア評価1/6将来の成長0/6過去の実績0/6財務の健全性4/6配当金0/6リスク分析キャッシュランウェイが1年未満である Swedish市場と比較して、過去 3 か月間の株価の変動が非常に大きい過去1年間で株主の希薄化は大幅に進んだ 過去5年間で収益は年間37.7%減少しました。 +2 さらなるリスクすべてのリスクチェックを見るPRLD Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueSEK Current PriceSEK 15.5021.3% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-135m222m2016201920222025202620282031Revenue SEK 221.7mEarnings SEK 29.8mAdvancedSet Fair ValueView all narrativesProlight Diagnostics AB (publ) 競合他社IntegrumSymbol: OM:INTEG BMarket cap: SEK 207.7mSolution International NordicsSymbol: NGM:SINMarket cap: SEK 155.9mMedclairSymbol: NGM:MCLRMarket cap: SEK 220.0mAcarixSymbol: OM:ACARIXMarket cap: SEK 323.0m価格と性能株価の高値、安値、推移の概要Prolight Diagnostics過去の株価現在の株価SEK 15.5052週高値SEK 052週安値SEK 0ベータ2.691ヶ月の変化5.01%3ヶ月変化-15.94%1年変化-35.15%3年間の変化-53.59%5年間の変化-88.83%IPOからの変化-57.99%最新ニュースBoard Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Chairman of the board Fredrik Alpsten was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.分析記事 • Apr 22Is Prolight Diagnostics (NGM:PRLD) In A Good Position To Invest In Growth?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...分析記事 • Dec 23Is Prolight Diagnostics (NGM:PRLD) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. For example, although...お知らせ • May 23Prolight Diagnostics AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 100.298496 million.Prolight Diagnostics AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 100.298496 million. Security Name: Shares Security Type: Common Stock Securities Offered: 501,492,480 Price\Range: SEK 0.2 Transaction Features: Rights OfferingRecent Insider Transactions Derivative • Oct 23CEO & Director exercised options to buy kr450k worth of stock.On the 18th of October, Ulf Bladin exercised options to buy 3m shares at a strike price of around kr0.12, costing a total of kr300k. This transaction amounted to 345% of their direct individual holding at the time of the trade. Since December 2023, Ulf has owned 724.64k shares directly. Company insiders have collectively bought kr358k more than they sold, via options and on-market transactions, in the last 12 months.New Risk • Oct 01New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr97.4m (US$9.48m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr38m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 75% per year over the past 5 years. Shareholders have been substantially diluted in the past year (112% increase in shares outstanding). Market cap is less than US$10m (kr97.4m market cap, or US$9.48m). Minor Risk Revenue is less than US$5m (kr25m revenue, or US$2.4m).最新情報をもっと見るRecent updatesBoard Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Chairman of the board Fredrik Alpsten was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.分析記事 • Apr 22Is Prolight Diagnostics (NGM:PRLD) In A Good Position To Invest In Growth?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...分析記事 • Dec 23Is Prolight Diagnostics (NGM:PRLD) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. For example, although...お知らせ • May 23Prolight Diagnostics AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 100.298496 million.Prolight Diagnostics AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 100.298496 million. Security Name: Shares Security Type: Common Stock Securities Offered: 501,492,480 Price\Range: SEK 0.2 Transaction Features: Rights OfferingRecent Insider Transactions Derivative • Oct 23CEO & Director exercised options to buy kr450k worth of stock.On the 18th of October, Ulf Bladin exercised options to buy 3m shares at a strike price of around kr0.12, costing a total of kr300k. This transaction amounted to 345% of their direct individual holding at the time of the trade. Since December 2023, Ulf has owned 724.64k shares directly. Company insiders have collectively bought kr358k more than they sold, via options and on-market transactions, in the last 12 months.New Risk • Oct 01New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr97.4m (US$9.48m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr38m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 75% per year over the past 5 years. Shareholders have been substantially diluted in the past year (112% increase in shares outstanding). Market cap is less than US$10m (kr97.4m market cap, or US$9.48m). Minor Risk Revenue is less than US$5m (kr25m revenue, or US$2.4m).Reported Earnings • Aug 30Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: kr4.16m (up 32% from 2Q 2023). Net loss: kr11.2m (loss widened 40% from 2Q 2023).お知らせ • Jun 25Prolight Diagnostics and TTP Provides Update on MicroFlex DevelopmentProlight Diagnostics and TTP have developed the Point-of-Care system MicroFlex which brings the benefits of central-lab quality ELISA testing to more distributed environments with a compact and more user-friendly package.Reported Earnings • May 22First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: kr3.40m (down 2.7% from 1Q 2023). Net loss: kr8.93m (loss widened 18% from 1Q 2023).お知らせ • Apr 19Prolight Diagnostics AB (publ) to Report Fiscal Year 2023 Results on Apr 23, 2024Prolight Diagnostics AB (publ) announced that they will report fiscal year 2023 results on Apr 23, 2024お知らせ • Apr 10Prolight Diagnostics AB (publ), Annual General Meeting, May 14, 2024Prolight Diagnostics AB (publ), Annual General Meeting, May 14, 2024, at 13:00 Central European Standard Time. Location: Company’s office, Gasverksgatan 3 A, 222 29 Lund Sweden Agenda: To Establishment and approval of the voting list; to discuss Approval of the agenda; to discuss Election of one or two persons to verify the minutes; to Determination as to whether the Meeting has been duly convened; to Presentation of the annual report and the auditor’s report as well as the group accounts and the auditor’s report for the group for the financial year 2023; and to discuss other matters.New Risk • Mar 04New major risk - Revenue and earnings growthEarnings have declined by 44% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr41m free cash flow). Earnings have declined by 44% per year over the past 5 years. Shareholders have been substantially diluted in the past year (77% increase in shares outstanding). Market cap is less than US$10m (kr100.0m market cap, or US$9.69m). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Revenue is less than US$5m (kr19m revenue, or US$1.8m).New Risk • Feb 04New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 76% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (76% increase in shares outstanding). Market cap is less than US$10m (kr100.9m market cap, or US$9.62m). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Revenue is less than US$5m (kr15m revenue, or US$1.5m).New Risk • Dec 13New major risk - Revenue and earnings growthEarnings have declined by 36% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr49m free cash flow). Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings have declined by 36% per year over the past 5 years. Market cap is less than US$10m (kr90.6m market cap, or US$8.67m). Minor Risk Revenue is less than US$5m (kr36m revenue, or US$3.5m).New Risk • Oct 27New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr83.8m (US$7.53m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Market cap is less than US$10m (kr83.8m market cap, or US$7.53m). Minor Risk Revenue is less than US$5m (kr11m revenue, or US$1.0m).分析記事 • Jul 14Is Prolight Diagnostics (NGM:PRLD) In A Good Position To Invest In Growth?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...New Risk • Jun 15New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr26m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 26% per year over the past 5 years. Revenue is less than US$1m (kr5.7m revenue, or US$538k). Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Market cap is less than US$100m (kr120.8m market cap, or US$11.3m).Recent Insider Transactions • Jan 22Board Member recently bought kr172k worth of stockOn the 18th of January, Tobias Volker bought around 500k shares on-market at roughly kr0.34 per share. This transaction amounted to 82% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr184k more in shares than they have sold in the last 12 months.Board Change • Nov 16No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. No independent directors (6 non-independent directors). Director Maria Holmlund is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Chairman of the Board Ingemar Kihlstrom was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.分析記事 • Nov 07Companies Like Prolight Diagnostics (NGM:PRLD) Can Afford To Invest In GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, although...分析記事 • Jul 06We Think Prolight Diagnostics (NGM:PRLD) Can Easily Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...分析記事 • Mar 09Companies Like Prolight Diagnostics (NGM:PRLD) Are In A Position To Invest In GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Is New 90 Day High Low • Feb 23New 90-day low: kr1.59The company is down 18% from its price of kr1.93 on 25 November 2020. The Swedish market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 16% over the same period.分析記事 • Nov 24Prolight Diagnostics (NGM:PRLD) Is In A Good Position To Deliver On Growth PlansEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Is New 90 Day High Low • Nov 18New 90-day low: kr1.81The company is down 51% from its price of kr3.74 on 20 August 2020. The Swedish market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 1.0% over the same period.Is New 90 Day High Low • Oct 21New 90-day low: kr2.24The company is down 14% from its price of kr2.61 on 23 July 2020. The Swedish market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 8.0% over the same period.株主還元PRLDSE Medical EquipmentSE 市場7D21.3%6.4%3.2%1Y-35.1%-1.8%14.4%株主還元を見る業界別リターン: PRLD過去 1 年間で-1.8 % の収益を上げたSwedish Medical Equipment業界を下回りました。リターン対市場: PRLDは、過去 1 年間で14.4 % のリターンを上げたSwedish市場を下回りました。価格変動Is PRLD's price volatile compared to industry and market?PRLD volatilityPRLD Average Weekly Movement13.5%Medical Equipment Industry Average Movement7.3%Market Average Movement6.3%10% most volatile stocks in SE Market13.4%10% least volatile stocks in SE Market3.7%安定した株価: PRLDの株価は、 Swedish市場と比較して過去 3 か月間で変動しています。時間の経過による変動: PRLDの weekly volatility ( 13% ) は過去 1 年間安定していますが、依然としてSwedishの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト199922Ulf Bladinprolightdx.comProlight Diagnostics AB (publish)は、スウェーデンでPOC検査に使用される診断システムを開発している。PLDマイクロフレックスとフレックスメンブレンの開発に従事。Prolight Diagnostics AB（publ）は1999年に設立され、スウェーデンのストックホルムを拠点としている。もっと見るProlight Diagnostics AB (publ) 基礎のまとめProlight Diagnostics の収益と売上を時価総額と比較するとどうか。PRLD 基礎統計学時価総額SEK 186.69m収益（TTM）-SEK 49.71m売上高(TTM)SEK 42.20m4.4xP/Sレシオ-3.8xPER（株価収益率PRLD は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計PRLD 損益計算書（TTM）収益SEK 42.20m売上原価SEK 0売上総利益SEK 42.20mその他の費用SEK 91.91m収益-SEK 49.71m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-4.13グロス・マージン100.00%純利益率-117.79%有利子負債／自己資本比率0%PRLD の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 16:40終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Prolight Diagnostics AB (publ) 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Board Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Chairman of the board Fredrik Alpsten was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
分析記事 • Apr 22Is Prolight Diagnostics (NGM:PRLD) In A Good Position To Invest In Growth?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
分析記事 • Dec 23Is Prolight Diagnostics (NGM:PRLD) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. For example, although...
お知らせ • May 23Prolight Diagnostics AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 100.298496 million.Prolight Diagnostics AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 100.298496 million. Security Name: Shares Security Type: Common Stock Securities Offered: 501,492,480 Price\Range: SEK 0.2 Transaction Features: Rights Offering
Recent Insider Transactions Derivative • Oct 23CEO & Director exercised options to buy kr450k worth of stock.On the 18th of October, Ulf Bladin exercised options to buy 3m shares at a strike price of around kr0.12, costing a total of kr300k. This transaction amounted to 345% of their direct individual holding at the time of the trade. Since December 2023, Ulf has owned 724.64k shares directly. Company insiders have collectively bought kr358k more than they sold, via options and on-market transactions, in the last 12 months.
New Risk • Oct 01New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr97.4m (US$9.48m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr38m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 75% per year over the past 5 years. Shareholders have been substantially diluted in the past year (112% increase in shares outstanding). Market cap is less than US$10m (kr97.4m market cap, or US$9.48m). Minor Risk Revenue is less than US$5m (kr25m revenue, or US$2.4m).
Board Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Chairman of the board Fredrik Alpsten was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
分析記事 • Apr 22Is Prolight Diagnostics (NGM:PRLD) In A Good Position To Invest In Growth?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
分析記事 • Dec 23Is Prolight Diagnostics (NGM:PRLD) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. For example, although...
お知らせ • May 23Prolight Diagnostics AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 100.298496 million.Prolight Diagnostics AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 100.298496 million. Security Name: Shares Security Type: Common Stock Securities Offered: 501,492,480 Price\Range: SEK 0.2 Transaction Features: Rights Offering
Recent Insider Transactions Derivative • Oct 23CEO & Director exercised options to buy kr450k worth of stock.On the 18th of October, Ulf Bladin exercised options to buy 3m shares at a strike price of around kr0.12, costing a total of kr300k. This transaction amounted to 345% of their direct individual holding at the time of the trade. Since December 2023, Ulf has owned 724.64k shares directly. Company insiders have collectively bought kr358k more than they sold, via options and on-market transactions, in the last 12 months.
New Risk • Oct 01New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr97.4m (US$9.48m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr38m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 75% per year over the past 5 years. Shareholders have been substantially diluted in the past year (112% increase in shares outstanding). Market cap is less than US$10m (kr97.4m market cap, or US$9.48m). Minor Risk Revenue is less than US$5m (kr25m revenue, or US$2.4m).
Reported Earnings • Aug 30Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: kr4.16m (up 32% from 2Q 2023). Net loss: kr11.2m (loss widened 40% from 2Q 2023).
お知らせ • Jun 25Prolight Diagnostics and TTP Provides Update on MicroFlex DevelopmentProlight Diagnostics and TTP have developed the Point-of-Care system MicroFlex which brings the benefits of central-lab quality ELISA testing to more distributed environments with a compact and more user-friendly package.
Reported Earnings • May 22First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: kr3.40m (down 2.7% from 1Q 2023). Net loss: kr8.93m (loss widened 18% from 1Q 2023).
お知らせ • Apr 19Prolight Diagnostics AB (publ) to Report Fiscal Year 2023 Results on Apr 23, 2024Prolight Diagnostics AB (publ) announced that they will report fiscal year 2023 results on Apr 23, 2024
お知らせ • Apr 10Prolight Diagnostics AB (publ), Annual General Meeting, May 14, 2024Prolight Diagnostics AB (publ), Annual General Meeting, May 14, 2024, at 13:00 Central European Standard Time. Location: Company’s office, Gasverksgatan 3 A, 222 29 Lund Sweden Agenda: To Establishment and approval of the voting list; to discuss Approval of the agenda; to discuss Election of one or two persons to verify the minutes; to Determination as to whether the Meeting has been duly convened; to Presentation of the annual report and the auditor’s report as well as the group accounts and the auditor’s report for the group for the financial year 2023; and to discuss other matters.
New Risk • Mar 04New major risk - Revenue and earnings growthEarnings have declined by 44% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr41m free cash flow). Earnings have declined by 44% per year over the past 5 years. Shareholders have been substantially diluted in the past year (77% increase in shares outstanding). Market cap is less than US$10m (kr100.0m market cap, or US$9.69m). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Revenue is less than US$5m (kr19m revenue, or US$1.8m).
New Risk • Feb 04New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 76% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (76% increase in shares outstanding). Market cap is less than US$10m (kr100.9m market cap, or US$9.62m). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Revenue is less than US$5m (kr15m revenue, or US$1.5m).
New Risk • Dec 13New major risk - Revenue and earnings growthEarnings have declined by 36% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr49m free cash flow). Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings have declined by 36% per year over the past 5 years. Market cap is less than US$10m (kr90.6m market cap, or US$8.67m). Minor Risk Revenue is less than US$5m (kr36m revenue, or US$3.5m).
New Risk • Oct 27New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr83.8m (US$7.53m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Market cap is less than US$10m (kr83.8m market cap, or US$7.53m). Minor Risk Revenue is less than US$5m (kr11m revenue, or US$1.0m).
分析記事 • Jul 14Is Prolight Diagnostics (NGM:PRLD) In A Good Position To Invest In Growth?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
New Risk • Jun 15New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr26m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 26% per year over the past 5 years. Revenue is less than US$1m (kr5.7m revenue, or US$538k). Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Market cap is less than US$100m (kr120.8m market cap, or US$11.3m).
Recent Insider Transactions • Jan 22Board Member recently bought kr172k worth of stockOn the 18th of January, Tobias Volker bought around 500k shares on-market at roughly kr0.34 per share. This transaction amounted to 82% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr184k more in shares than they have sold in the last 12 months.
Board Change • Nov 16No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. No independent directors (6 non-independent directors). Director Maria Holmlund is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Chairman of the Board Ingemar Kihlstrom was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
分析記事 • Nov 07Companies Like Prolight Diagnostics (NGM:PRLD) Can Afford To Invest In GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, although...
分析記事 • Jul 06We Think Prolight Diagnostics (NGM:PRLD) Can Easily Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
分析記事 • Mar 09Companies Like Prolight Diagnostics (NGM:PRLD) Are In A Position To Invest In GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Is New 90 Day High Low • Feb 23New 90-day low: kr1.59The company is down 18% from its price of kr1.93 on 25 November 2020. The Swedish market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 16% over the same period.
分析記事 • Nov 24Prolight Diagnostics (NGM:PRLD) Is In A Good Position To Deliver On Growth PlansEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Is New 90 Day High Low • Nov 18New 90-day low: kr1.81The company is down 51% from its price of kr3.74 on 20 August 2020. The Swedish market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 1.0% over the same period.
Is New 90 Day High Low • Oct 21New 90-day low: kr2.24The company is down 14% from its price of kr2.61 on 23 July 2020. The Swedish market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 8.0% over the same period.
